DiaSorin S p A signs a supplier agreement with Quest Diagnostics for the innovative molecular multiplexing platform, LIAISON PLEX

Diasorin signs a supplier agreement with Quest Diagnostics for the innovative molecular multiplexing platform, LIAISON PLEX

Under the terms of the agreement, Diasorin will:

• deploy 24 LIAISON PLEX systems in eight Quest Diagnostics Laboratories in the United States, expanding access to advanced molecular multiplexing technology

• supply the LIAISON PLEX Respiratory Panel to meet demand for respiratory testing during the upcoming flu season

Saluggia, Italy - October 22, 2025 - Diasorin (FTSE MIB: DIA) today announced the signing of a supplier agreement with Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services based in and serving the United States.

Under the terms of the agreement, Diasorin will install 24 LIAISON PLEX systems in 8 Quest Diagnostics laboratories in the U.S. Each LIAISON PLEX®system has 6 chambers allowing for high-volume testing.

Diasorin expects to supply its LIAISON PLEX Respiratory Panel to Quest Diagnostics to serve demand for molecular testing during the upcoming flu season.

This agreement marks a pivotal milestone in Diasorin's multiplexing strategy and underscores the increasing recognition of the LIAISON PLEX platform's advanced technical capabilities, usability, and diagnostic accuracy.

"We are proud to see our technology embraced by one of the largest laboratory net

orks in the U.S.," said Angelo Rago, President of Luminex. "This agreement validates the value of our multiplexing platform in supporting laboratories to deliver more informed diagnostic insights hile maintaining operational simplicity."

About Diasorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 31 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at https://www.diasorin.com

For additional information, please contact: Investor Relations Riccardo Fava Eugenia Ragazzo

Corporate VP Communication, ESG & Investor Relations Corporate Investor Relations & ESG Senior Analyst

riccardo.fava@diasorin.com eugenia.ragazzo@diasorin.com